Amylyx locks in avexitide manufacturing, taking $30M pre-approval capacity risk

Commercial readiness was expected; the contracts are the new information. Amylyx had already positioned avexitide for potential commercialization if approved, so securing manufacturing capacity is directionally consistent with the standing plan rather than a wholly unexpected strategic pivot. The filing now turns that plan into concrete supplier commitments: Bachem and Polypeptide will supply avexitide drug substance for commercial use, if approved. 〔0〕

The positive is supply de-risking, not improved clinical odds. Two non-exclusive manufacturers give Amylyx more than one commercial source and provide capacity planning ahead of a potential launch. The Bachem agreement begins with a five-year term, while the Polypeptide arrangement remains only a term sheet pending a definitive agreement. 〔1〕

The trade-off is meaningful pre-approval cash and purchase exposure. Amylyx must pay Polypeptide $30 million for capacity reservation and accept minimum annual purchase requirements beginning in 2028, even though regulatory approval is not yet secured. The filing does not disclose the minimum volumes, supply prices, or total future purchase obligations, so the economic burden cannot yet be fully assessed.

Net read: strategically sensible, but not an unqualified positive surprise. The agreements reduce a potential manufacturing bottleneck if avexitide succeeds, but they also lock in capital and volume commitments before approval and before the Polypeptide contract is final. With no clean consensus benchmark for a supply agreement, this lands as a mixed event: operationally constructive, financially and commercially conditional.